Biogen and its development partner Eisai Inc. announced Friday they have halted work on one of their remaining treatments due to what they said is a poor risk-benefit outlook.

source https://finance.yahoo.com/m/ccafe7cd-5a66-354e-a162-9ce82dba9bbf/biogen%2C-eisai-halt-work-on.html?.tsrc=rss